A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Background: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Traditionally, COPD management has relied on bronchodilators, pulmonary rehabilitation, steroids, and invasive options like lung transplantation or lung volume reduction surgery, leaving a gap in ...

A combination of lifestyle changes, pulmonary rehab, and treatments like bronchodilators and corticosteroids can help COPD patients live as fully and well as possible.

It’s something Lindsay Bishop is seeing more and more of in her role as COPD educator for Open Airways. COPD is a chronic lung condition characterised by swollen, inflamed airways and excessive ...

This broad utilization across all patient types is consistent with market research and supports our belief that Ohtuvayre’s bronchodilator ... advancement for COPD patients and can re-define ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...

Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti ...

For the 16 million Americans with chronic obstructive pulmonary disease (COPD), travel can be as anxiety-provoking as it is life-affirming. The fatigue, chest tightness, congestion, and difficulty ...

LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ...